Genelux Corporation Rings the Opening Bell in Celebration of its IPO

About This Event

Genelux Corporation (Nasdaq: GNLX), a late clinical-stage biopharmaceutical company focused on developing a pipeline of next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types, visits the Nasdaq MarketSite in Times Square.

In honor of the occasion, Thomas Zindrick, President and Chief Executive Officer, rings the Opening Bell.

Nasdaq Originals Exclusive insights on the forces shaping the convergence of technology, business and sports. Explore